Updated on 2021/05/06

写真a

 
YOGO Naoyuki
 
Organization
Institutes of Innovation for Future Society Industry-Academia Cooperative Research Course Designated assistant professor
Title
Designated assistant professor
Contact information
メールアドレス

Degree 1

  1. Doctor of Philosophy (Medical Science) ( 2021.3   Nagoya University ) 

Research Areas 3

  1. Nanotechnology/Materials / Nanobioscience

  2. Life Science / Tumor diagnostics and therapeutics

  3. Life Science / Respiratory medicine

Current Research Project and SDGs 1

  1. イムノウォールデバイス開発

Research History 4

  1. Nagoya University   Institute of Innovation for Future Society   Designated assistant professor

    2020.4

      More details

    Country:Japan

  2. Nagoya University   Nano-Life System, Institute of Innovation for Future Society

    2019.12 - 2020.3

  3. Nagoya University   Hospital, Hospital   Assistant professor of hospital

    2019.4 - 2020.3

  4. Nagoya University   Graduate School of Engineering, Biomolecular Engineering   Researcher

    2017.4 - 2019.3

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    2013.4 - 2017.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1999.4 - 2005.3

      More details

    Country: Japan

Professional Memberships 7

  1. 日本内科学会   会員

  2. 日本呼吸器学会   会員

  3. 日本呼吸器内視鏡学会   会員

  4. 日本アレルギー学会   会員

  5. 日本肺癌学会   会員

  6. 日本感染症学会   会員

  7. 日本医師会

▼display all

 

Papers 26

  1. Comparing incidences of infusion site reactions between brand-name and generic vinorelbine in patients with non-small cell lung cancer. Reviewed International journal

    Naoya Ozawa, Tetsunari Hase, Takahiro Hatta, Atsunobu Sagara, Kazuya Ichikawa, Masayuki Miyazaki, Naoyuki Yogo, Masahiko Ando, Naozumi Hashimoto, Kiyofumi Yamada, Yoshinori Hasegawa

    British journal of clinical pharmacology   Vol. 87 ( 3 ) page: 1318 - 1326   2021.3

     More details

    Publishing type:Research paper (scientific journal)  

    AIM: This study aimed to compare the incidence of infusion site reactions (ISRs) induced by intravenous administration of brand-name and generic vinorelbine (VNR) for treating non-small cell lung cancer. METHOD: This single-centre retrospective cohort study was conducted by medical chart review of VNR infusions. ISRs were defined as symptoms around the infusion site, including pain, redness, and swelling. ISRs requiring treatment were defined as ISRs requiring treatments including steroid ointments, vein re-puncture, and local steroid injections. RESULTS: In all, 1973 VNR infusions were administered to 340 patients (brand-name, 141 patients; generic, 199 patients). ISRs and ISRs requiring treatment were observed in 161 and 100 patients, respectively. The ISR incidence per patient and per injection were significantly higher in generic VNR-treated patients than in brand-name VNR-treated patients (53.3% vs. 39.0%, P = 0.0112, and 15.0% vs. 9.9%, P = 0.0008, respectively). The frequency of ISRs requiring treatment was also significantly higher in the generic group (per patient: 36.7% vs. 19.2%, P = 0.0005; per injection: 11.3% vs. 5.5%, P < 0.0001). Multivariate analysis revealed that generic VNR was significantly associated with an increased risk of ISRs (per patient: adjusted odds ratio [AOR] 1.775, P = 0.0155; per injection: AOR 1.672, P = 0.004) and ISRs requiring treatment (per patient: AOR 2.422, P = 0.0012; per injection: AOR 2.286, P = 0.001). CONCLUSION: Intravenous infusion of generic VNR was associated with an increased risk of ISRs. Further research is needed to elucidate the mechanism underlying the increased incidence of ISRs with generic VNR.

    DOI: 10.1111/bcp.14516

    Web of Science

    Scopus

    PubMed

  2. Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients. International journal

    Naoyuki Yogo, Tetsunari Hase, Toshihiro Kasama, Keine Nishiyama, Naoya Ozawa, Takahiro Hatta, Hirofumi Shibata, Mitsuo Sato, Kazuki Komeda, Nozomi Kawabe, Kohei Matsuoka, Toyofumi Fengshi Chen-Yoshikawa, Noritada Kaji, Manabu Tokeshi, Yoshinobu Baba, Yoshinori Hasegawa

    PloS one   Vol. 15 ( 11 ) page: e0241422   2020.11

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Public Library of Science ({PLoS})  

    Detecting molecular targets in specimens from patients with lung cancer is essential for targeted therapy. Recently, we developed a highly sensitive, rapid-detection device (an immuno-wall device) that utilizes photoreactive polyvinyl alcohol immobilized with antibodies against a target protein via a streptavidin-biotin interaction. To evaluate its performance, we assayed epidermal growth factor receptor (EGFR) mutations, such as E746_A750 deletion in exon 19 or L858R substitution in exon 21, both of which are common in non-small cell lung cancer and important predictors of the treatment efficacy of EGFR tyrosine kinase inhibitors. The results showed that in 20-min assays, the devices detected as few as 1% (E746_A750 deletion) and 0.1% (L858R substitution) of mutant cells. Subsequent evaluation of detection of the mutations in surgically resected lung cancer specimens from patients with or without EGFR mutations and previously diagnosed using commercially available, clinically approved genotyping assays revealed diagnostic sensitivities of the immuno-wall device for E746_A750 deletion and L858R substitution of 85.7% and 87.5%, respectively, with specificities of 100% for both mutations. These results suggest that the immuno-wall device represents a good candidate next-generation diagnostic tool, especially for screening of EGFR mutations.

    DOI: 10.1371/journal.pone.0241422

    Web of Science

    Scopus

    PubMed

  3. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study. Reviewed

    Tetsunari Hase, Masayuki Miyazaki, Kazuya Ichikawa, Naoyuki Yogo, Naoya Ozawa, Takahiro Hatta, Masahiko Ando, Mitsuo Sato, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa

    International journal of clinical oncology   Vol. 25 ( 11 ) page: 1928 - 1935   2020.11

     More details

    Publishing type:Research paper (scientific journal)  

    BACKGROUND: Intravenous administration of magnesium with a short hydration regimen is recommended for patients receiving high-dose cisplatin to protect against cisplatin-induced nephrotoxicity. However, the optimal dose of magnesium supplementation has not been clarified. The aim of this trial was to investigate the safety and efficacy of a short hydration regimen with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy. METHODS: The key eligibility criteria included cytologically or histologically diagnosed lung cancer, candidacy for cisplatin-based (≥ 60 mg/m2) chemotherapy or chemoradiotherapy, no prior chemotherapy, aged 20-75 years, and adequate renal function. Cisplatin was administered with pre-hydration with 20 mEq of magnesium sulfate. Mannitol was administered just before cisplatin infusion to enforce diuresis. The primary endpoint was the proportion of patients who underwent cisplatin-based chemotherapy with a short hydration regimen with 20 mEq of magnesium supplementation without a grade 2 or higher elevation in creatinine. RESULTS: Forty patients with a median age of 66 years (range 35-74) were prospectively enrolled. Median baseline creatinine was 0.71 mg/dL. Median dose of cisplatin in the first cycle was 80 mg/m2. In the first cycle, no patients developed grade 2 creatinine toxicity. During the treatment period, one patient developed grade 2 creatinine elevation; thus, the proportion of patients without a grade 2 or higher elevation in creatinine was 97.5% (95% confidence interval 86.8-99.9). CONCLUSION: A short hydration regimen with 20 mEq of magnesium supplementation is safe and feasible for patients with lung cancer receiving cisplatin-based chemotherapy.

    DOI: 10.1007/s10147-020-01755-1

    Web of Science

    Scopus

    PubMed

  4. Exosomal Analysis of ALK Rearrangements by Spin Column with Porous Glass Filter

    Hatta T., Hase T., Ozawa N., Yogo N., Yukawa H., Tanaka H., Onoshima D., Sato M., Hori M., Baba Y., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY   Vol. 14 ( 10 ) page: S676 - S676   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  5. The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer

    Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE   Vol. 109   page: 1181-1181   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  6. The Subunit eIF2 ss of Translation- Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer Reviewed

    Sato Mitsuo, Tanaka Ichidai, Goto Daiki, Kato Toshio, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

    CANCER SCIENCE   Vol. 109   page: 1181   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  7. Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer

    Yogo N., Hase T., Kasama T., Hatta T., Ozawa N., Sato M., Kaji N., Tokeshi M., Baba Y., Hasegawa Y.

    ANNALS OF ONCOLOGY   Vol. 29   page: .   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  8. Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer

    Yogo N, Hase T, Kasama T, Hatta T, Ozawa N, Sato M, Kaji N, Tokeshi M, Baba Y, Hasegawa Y

    ANNALS OF ONCOLOGY   Vol. 29   page: .   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  9. Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy

    Hase T., Miyazaki M., Ichikawa K., Yogo N., Ozawa N., Ando M., Morise M., Sato M., Kondo M., Yamada K., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY   Vol. 13 ( 10 ) page: S880-S880   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  10. eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer Reviewed

    Ichidai Tanaka, Mitsuo Sato, Toshio Kato, Daiki Goto, Tomohiko Kakumu, Ayako Miyazawa, Naoyuki Yogo, Tetsunari Hase, Masahiro Morise, Yoshitaka Sekido, Luc Girard, John D. Minna, Lauren A. Byers, John V. Heymach, Kevin R. Coombes, Masashi Kondo, Yoshinori Hasegawa

    Cancer Science   Vol. 109 ( 6 ) page: 1843 - 1852   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Blackwell Publishing Ltd  

    To identify novel therapeutic targets for non-small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification of potential target gene(s) through shRNA functional screens in 2 independent NSCLC cell lines
    (ii) validation of the clinical relevance of identified gene(s) using public databases
    and (iii) investigation of therapeutic potential of targeting the identified gene(s) in vitro. A semi-genome-wide shRNA screen was performed in NCI-H358 cells, and was integrated with data from our previous screen in NCI-H460 cells. Among genes identified in shRNA screens, 24 were present in both NCI-H358 and NCI-H460 cells and were considered potential targets. Among the genes, we focused on eIF2β, which is a subunit of heterotrimeric G protein EIF2 and functions as a transcription initiation factor. The eIF2β protein is highly expressed in lung cancer cell lines compared with normal bronchial epithelial cells, and gene copy number analyses revealed that eIF2β is amplified in a subset of NSCLC cell lines. Gene expression analysis using The Cancer Genome Atlas (TCGA) dataset revealed that eIF2β expression is significantly upregulated in lung cancer tissues compared with corresponding normal lung tissues. Furthermore, high eIF2β expression was correlated with poor survival in patients with lung adenocarcinoma, as shown in other cohorts using publicly available online tools. RNAi-mediated depletion of eIF2β suppresses growth of lung cancer cells independently of p53 mutation status, in part through G1 cell cycle arrest. Our data suggest that eIF2β is a therapeutic target for lung cancer.

    DOI: 10.1111/cas.13602

    Web of Science

    Scopus

    PubMed

  11. Development of the immuno-wall device for rapid, low-cost detection of EGFR mutations in tumor samples from patients with lung cancer

    Yogo N., Hase T., Kasama T., Ozawa N., Sato M., Kaji N., Tokeshi M., Baba Y., Hasegawa Y.

    ANNALS OF ONCOLOGY   Vol. 28   page: .   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  12. Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen

    Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.

    JOURNAL OF THORACIC ONCOLOGY   Vol. 12 ( 11 ) page: S2277-S2278   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  13. Development of the immuno-wall device for rapid, low-cost detection of EGFR mutations in tumor samples from patients with lung cancer Reviewed

    Yogo N, Hase T, Kasama T, Ozawa N, Sato M, Kaji N, Tokeshi M, Baba Y, Hasegawa Y

    ANNALS OF ONCOLOGY   Vol. 28   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  14. Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer

    Tomohiko Kakumu, Mitsuo Sato, Daiki Goto, Toshio Kato, Naoyuki Yogo, Tetsunari Hase, Masahiro Morise, Takayuki Fukui, Kohei Yokoi, Yoshitaka Sekido, Luc Girard, John D. Minna, Lauren A. Byers, John V. Heymach, Kevin R. Coombes, Masashi Kondo, Yoshinori Hasegawa

    Cancer Science   Vol. 108 ( 4 ) page: 732 - 743   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Blackwell Publishing Ltd  

    To identify potential therapeutic targets for lung cancer, we performed semi-genome-wide shRNA screening combined with the utilization of genome-wide expression and copy number data. shRNA screening targeting 5043 genes in NCI-H460 identified 51 genes as candidates. Pathway analysis revealed that the 51 genes were enriched for the five pathways, including ribosome, proteasome, RNA polymerase, pyrimidine metabolism and spliceosome pathways. We focused on the proteasome pathway that involved six candidate genes because its activation has been demonstrated in diverse human malignancies, including lung cancer. Microarray expression and array CGH data showed that PSMA6, a proteasomal subunit of a 20S catalytic core complex, was highly expressed in lung cancer cell lines, with recurrent gene amplifications in some cases. Therefore, we further examined the roles of PSMA6 in lung cancer. Silencing of PSMA6 induced apoptosis or G2/M cell cycle arrest in cancer cell lines but not in an immortalized normal lung cell line. These results suggested that PSMA6 serves as an attractive target with a high therapeutic index for lung cancer.

    DOI: 10.1111/cas.13185

    Web of Science

    Scopus

    PubMed

  15. Cytochrome c oxidase subunit 5a (COX5A) is identified as a potential therapeutic target for lung cancer with high therapeutic index through a pooled shRNA screen Reviewed

    Toshio Kato, Mitsuo Sato, Masashi Kondo, Tomohiko Kakumu, Naoyuki Yogo, Tetsunari Hase, Masahiro Morise, Yoshionori Hasegawa, John D. Minnna, Luc Girard

    CANCER RESEARCH   Vol. 76   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-206

    Web of Science

  16. Cyclin-Dependent kinase11 (CDK11) Is Crucial for Growth of Lung Cancer Cells

    Kakumu Tomohiko, Sato Mitsuo, Kato Toshio, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Kondo Masashi, Sekido Yoshitaka, Hasegawa Yoshinori

    JOURNAL OF THORACIC ONCOLOGY   Vol. 10 ( 9 ) page: S472-S472   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  17. Cyclin-Dependent kinase11 (CDK11) Is Crucial for Growth of Lung Cancer Cells Reviewed

    Tomohiko Kakumu, Mitsuo Sato, Toshio Kato, Naoyuki Yogo, Tetsunari Hase, Masahiro Morise, Masashi Kondo, Yoshitaka Sekido, Yoshinori Hasegawa

    JOURNAL OF THORACIC ONCOLOGY   Vol. 10 ( 9 ) page: S472 - S472   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    Web of Science

  18. Development of Microfluidic Devices for Rapid, Low-Cost Detection of EGFR Mutations in Cytological Samples from Patients with Lung Cancer

    Hase Tetsunari, Kasama Toshihiro, Nishiwaki Nanako, Yogo Naoyuki, Sato Mitsuo, Kaji Noritada, Kondo Masashi, Tokeshi Manabu, Baba Yoshinobu, Hasegawa Yoshinori

    JOURNAL OF THORACIC ONCOLOGY   Vol. 10 ( 9 ) page: S585 - S585   2015.9

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  19. Development of Microfluidic Devices for Rapid, Low-Cost Detection of EGFR Mutations in Cytological Samples from Patients with Lung Cancer Reviewed

    Tetsunari Hase, Toshihiro Kasama, Nanako Nishiwaki, Naoyuki Yogo, Mitsuo Sato, Noritada Kaji, Masashi Kondo, Manabu Tokeshi, Yoshinobu Baba, Yoshinori Hasegawa

    JOURNAL OF THORACIC ONCOLOGY   Vol. 10 ( 9 ) page: S585 - S585   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    Web of Science

  20. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells Reviewed

    Ryo Yamashita, Mitsuo Sato, Tomohiko Kakumu, Tetsunari Hase, Naoyuki Yogo, Eiichi Maruyama, Yoshitaka Sekido, Masashi Kondo, Yoshinori Hasegawa

    CANCER MEDICINE   Vol. 4 ( 4 ) page: 551 - 564   2015.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Both pro- and anti-oncogenic roles of miR-221 and miR-222 microRNAs are reported in several types of human cancers. A previous study suggested their oncogenic role in invasiveness in lung cancer, albeit only one cell line (H460) was used. To further evaluate involvement of miR-221 and miR-222 in lung cancer, we investigated the effects of miR-221 and miR-222 overexpression on six lung cancer cell lines, including H460, as well as one immortalized normal human bronchial epithelial cell line, HBEC4. miR-221 and miR-222 induced epithelial-to-mesenchymal transition (EMT)-like changes in a minority of HBEC4 cells but, unexpectedly, both the microRNAs rather suppressed their invasiveness. Consistent with the prior report, miR-221 and miR-222 promoted growth in H460; however, miR-221 suppressed growth in four other cell lines with no effects in one, and miR-222 suppressed growth in three cell lines but promoted growth in two. These are the first results to show tumor-suppressive effects of miR-221 and miR-222 in lung cancer cells, and we focused on clarifying the mechanisms. Cell cycle and apoptosis analyses revealed that growth suppression by miR-221 and miR-222 occurred through intra-S-phase arrest and/or apoptosis. Finally, lung cancer cell lines transfected with miR-221 or miR-222 became more sensitive to the S-phase targeting drugs, possibly due to an increased S-phase population. In conclusion, our data are the first to show tumor-suppressive effects of miR-221 and miR-222 on lung cancer, warranting testing their potential as therapeutics for the disease.

    DOI: 10.1002/cam4.412

    Web of Science

    Scopus

    PubMed

  21. P2-9-7 気管支閉鎖症の2例(気道狭窄,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    近藤 千晶, 鈴木 嘉洋, 鈴木 妙子, 岡地 祥太郎, 今井 直幸, 長谷 哲成, 麻生 裕紀, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 渡辺 尚宏, 長谷川 好規, 與語 直之, 宮崎 晋一, 加藤 俊夫, 織田 恒幸, 大舘 満, 松下 明弘, 中平 健一

    気管支学   Vol. 36 ( 0 )   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18907/jjsre.36.Special_S282_4

    CiNii Article

  22. P1-9-6 キシロカインアレルギー症例に対してテトラカインを用いて気管支鏡を施行した2例(安全対策,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    鈴木 嘉洋, 織田 恒幸, 中平 健一, 鈴木 妙子, 岡地 祥太郎, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 今井 直幸, 長谷川 好規, 松下 明弘, 宮崎 晋一, 與語 直之, 大舘 満, 加藤 俊夫, 近藤 千晶, 渡辺 尚宏

    気管支学   Vol. 36 ( 0 )   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18907/jjsre.36.Special_S248_3

    CiNii Article

  23. P1-8-1 経気管支肺生検にて確定診断がついたIntravascular large B-cell lymphomaの一例(びまん性疾患/BAL 2,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    織田 恒幸, 與語 直之, 渡辺 尚宏, 鈴木 嘉洋, 中平 健一, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 今井 直幸, 長谷川 好規, 岡地 祥太郎, 鈴木 妙子, 近藤 千晶, 松下 明弘, 大舘 満, 加藤 俊夫, 宮崎 晋一

    気管支学   Vol. 36 ( 0 )   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18907/jjsre.36.Special_S245_1

    CiNii Article

  24. P1-12-2 当院にて経験したEWSを用いた気管支充填術9症例の検討(EWS 1,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    中平 健一, 渡辺 尚宏, 鈴木 嘉洋, 鈴木 妙子, 岡地 群太郎, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 今井 直幸, 長谷川 好規, 松下 明弘, 大舘 満, 織田 恒幸, 加藤 俊夫, 近藤 千晶, 宮崎 晋一, 與語 直之

    気管支学   Vol. 36 ( 0 )   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18907/jjsre.36.Special_S253_2

    CiNii Article

  25. CBDCA plus PEMETREXED plus BEVACIZUMAB AND ITS MAINTENANCE CHEMOTHERAPY AS A SECOND LINE IN A CASE OF SOLE BREAST METASTASIS FROM LUNG ADENOCARCINOMA AFTER COMPLETE RESPONSE BY GEFITINIB AS A FIRST-LINE CHEMOTHERAPY Reviewed

    K. Sato, M. Yoshihara, Y. Takeyama, N. Yogo, M. Ohdate, Y. Fukui, H. Gonda, R. Suzuki

    ANNALS OF ONCOLOGY   Vol. 23   page: 146 - 146   2012.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OXFORD UNIV PRESS  

    Web of Science

  26. P12-3 当院における超音波気管支内視鏡ガイド下針生検(EBUS-TBNA)自験例56例の検討(EBUS3,ポスター12,第35回日本呼吸器内視鏡学会学術集会)

    佐藤 和秀, 竹山 佳宏, 梶川 茂久, 與語 直之, 大舘 満, 福井 保太, 権田 秀雄, 鈴木 隆二郎

    気管支学   Vol. 34 ( 0 )   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18907/jjsre.34.Special_S218_3

    CiNii Article

▼display all

MISC 30

  1. 肺癌における迅速なEGFR・ALK・ROS1遺伝子検査を目的としたマイクロ免疫診断チップ開発

    與語直之, 長谷哲成, 笠間敏博, 八田貴広, 小沢直也, 佐藤光夫, 馬場嘉信, 長谷川好規

    日本内科学会雑誌   Vol. 108 ( Suppl. ) page: 283 - 283   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

  2. eIF2b is a Potential Therapeutic Target for Non-small Cell Lung Cancer(和訳中)

    田中 一大, 佐藤 光夫, 加藤 俊夫, 後藤 大輝, 各務 智彦, 宮沢 亜矢子, 與語 直之, 長谷 哲成, 森瀬 昌宏, 関戸 好孝, 近藤 征史, 長谷川 好規

    肺癌   Vol. 58 ( 6 ) page: 669 - 669   2018.10

     More details

    Language:English   Publisher:(NPO)日本肺癌学会  

  3. 非小細胞肺癌に対する新規治療標的としての転写開始因子EIF2サブユニットEIF2β(The Subunit eIF2β of Translation-Initiation Factor EIF2 Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer)

    佐藤 光夫, 田中 一大, 後藤 大輝, 加藤 俊夫, 各務 智彦, 宮沢 亜矢子, 與語 直之, 長谷 哲成, 森瀬 昌弘, 関戸 好孝, 近藤 征史, 長谷川 好規

    日本癌学会総会記事   Vol. 77回   page: 1819 - 1819   2018.9

     More details

    Language:English   Publisher:日本癌学会  

  4. 肺癌体細胞変異の免疫学的診断システムの開発 組織検体におけるEGFR遺伝子変異の検出

    與語 直之, 長谷 哲成, 小沢 直也, 佐藤 光夫, 長谷川 好規

    気管支学   Vol. 40 ( Suppl. ) page: S224 - S224   2018.5

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

  5. イムノウォールデバイスの開発と遺伝子変異たんぱく質の検出

    中股征哉, 笠間敏博, 笠間敏博, 長谷哲成, 與語直之, 與語直之, 小沢直也, 真栄城正寿, 石田晃彦, 佐藤光夫, 加地範匡, 谷博文, 長谷川好規, 馬場嘉信, 馬場嘉信, 渡慶次学

    化学系学協会北海道支部冬季研究発表会(Web)   Vol. 2018   page: ROMBUNNO.2C18 (WEB ONLY)   2018

     More details

    Language:Japanese  

    J-GLOBAL

  6. 胸水細胞ライセート中の肺癌関連タンパク検出デバイスの開発

    石川広弥, 笠間敏博, 與語直之, 長谷哲成, 小野島大介, 湯川博, 近藤征史, 加地範匡, 長谷川好規, 馬場嘉信, 馬場嘉信

    化学とマイクロ・ナノシステム学会研究会講演要旨集   Vol. 36th   page: 68   2017.10

     More details

    Language:Japanese  

    J-GLOBAL

  7. スプライシング因子EFTUD2のノックダウンは非小細胞肺癌細胞株の増殖を抑制する

    加藤 俊夫, 佐藤 光夫, 長谷 哲成, 森瀬 昌宏, 與語 直之, 後藤 大輝, 宮沢 亜矢子, 近藤 征史, 長谷川 好規

    肺癌   Vol. 57 ( 5 ) page: 443 - 443   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  8. 胸水細胞溶解液中の肺癌関連タンパク検出デバイスの開発

    石川広弥, 笠間敏博, 與語直之, 長谷哲成, 近藤征史, 加地範匡, 長谷川好規, 馬場嘉信

    日本化学会春季年会講演予稿集(CD-ROM)   Vol. 97th   page: ROMBUNNO.2A1‐18   2017.3

     More details

    Language:Japanese  

    J-GLOBAL

  9. 翻訳開始因子Eurokaryotic initiation factor 2 subunit 2(EIF2S2)は非小細胞肺癌細胞株の増殖を抑制する

    加藤 俊夫, 佐藤 光夫, 與語 直之, 長谷 哲成, 森瀬 昌宏, 後藤 大輝, 宮沢 亜矢子, 近藤 征史, 長谷川 好規

    肺癌   Vol. 56 ( 6 ) page: 685 - 685   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  10. 肺がん患者に対するシスプラチン併用化学療法に関する、short hydration法の安全性評価

    與語 直之, 長谷 哲成, 後藤 大輝, 宮沢 亜矢子, 加藤 俊夫, 森瀬 昌宏, 佐藤 光夫, 近藤 征史, 荒木 理沙, 市川 和哉, 宮崎 雅之, 長谷川 好規

    肺癌   Vol. 56 ( 6 ) page: 717 - 717   2016.11

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  11. 肺癌治療標的としてのプロテアソームサブユニット遺伝子PSMA6

    佐藤 光夫, 各務 智彦, 加藤 俊夫, 與語 直之, 長谷 哲成, 森瀬 昌宏, 福井 高幸, 横井 香平, Girard Luc, Minna John, 近藤 征史, 長谷川 好規

    日本癌学会総会記事   Vol. 75回   page: E - 1085   2016.10

     More details

    Language:English   Publisher:日本癌学会  

  12. 胸水細胞溶解液中の遺伝子変異型上皮成長因子受容体検出デバイスの開発

    石川広弥, 笠間敏博, 與語直之, 長谷哲成, 近藤征史, 加地範匡, 長谷川好規, 馬場嘉信

    日本化学会春季年会講演予稿集(CD-ROM)   Vol. 96th   page: ROMBUNNO.1PB‐048   2016.3

     More details

    Language:Japanese  

    J-GLOBAL

  13. 肺癌体細胞遺伝子変異の免疫学的診断デバイスの開発

    笠間敏博, 笠間敏博, 長谷哲成, 石川広弥, 石川広弥, 與語直之, 近藤征史, 加地範匡, 加地範匡, 加地範匡, 渡慶次学, 渡慶次学, 渡慶次学, 長谷川好規, 長谷川好規, 馬場嘉信, 馬場嘉信, 馬場嘉信, 馬場嘉信

    化学とマイクロ・ナノシステム学会研究会講演要旨集   Vol. 32nd   page: 111   2015.11

     More details

    Language:Japanese  

    J-GLOBAL

  14. 肺がん治療標的としてのCDK11の可能性

    各務 智彦, 佐藤 光夫, 加藤 俊夫, 與語 直之, 長谷 哲成, 森瀬 昌宏, 近藤 政史, 関戸 好孝, 長谷川 好規

    日本癌学会総会記事   Vol. 74回   page: P - 2212   2015.10

     More details

    Language:English   Publisher:日本癌学会  

  15. Development of Microfluidic Devices for Rapid, Low-Cost Detection of EGFR Mutations in Cytological Samples from Patients with Lung Cancer Reviewed

    Hase Tetsunari, Kasama Toshihiro, Nishiwaki Nanako, Yogo Naoyuki, Sato Mitsuo, Kaji Noritada, Kondo Masashi, Tokeshi Manabu, Baba Yoshinobu, Hasegawa Yoshinori

    JOURNAL OF THORACIC ONCOLOGY   Vol. 10 ( 9 ) page: S585-S585   2015.9

     More details

    Language:English  

    Web of Science

  16. 気管支鏡で直視所見を有する症例に対するガイドシース併用気管支腔内超音波断層法(EBUS-GS)併用気管支内生検の有用性と安全性の検討

    伊藤 亮太, 今井 直幸, 高嶋 浩司, 與語 直之, 岡地 祥太郎, 青山 大輔, 犬飼 朗博, 安藤 昌彦, 今泉 和良, 長谷川 好規

    気管支学   Vol. 37 ( 4 ) page: 375 - 381   2015.7

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

    背景. 直視所見を有する病変には直視下で生検、擦過、洗浄などを施行し、診断を試みることが多いが、出血により十分な検査が施行できない場合がある。目的. ガイドシース挿入可能な直視所見を有する病変に対してEBUS-GS法を行い、その有効性と安全性について検討した。方法. 2009年4月7日から2014年1月21日までに、名古屋大学附属病院で直視所見を有する病変に対してEBUS-GS併用気管支内生検を行った15症例(GS群)を対象とし、その診断率と安全性を検討した。また直視下で生検を行った27症例を直視生検群とし、比較検討を行った。結果. 全15症例中、14例(93.3%)で診断可能であり、重篤な合併症は認められなかった。GS群の病変部位は区域支が主であり(14例/15例[93.3%])、またGS群における診断率は直視生検群と比較し、93.3%と85.2%で有意差は認めなかった。なお病変が粘膜下病変であるもしくは壊死組織に覆われている場合に、生検による病理組織診断が得られにくい傾向を認めた。生検回数はGS群、直視生検群でそれぞれ中央値9回(6〜12回)と7回(5〜9回)であり、GS群で有意に多かった(P=0.012)。またGS/直視生検併用群6例を除いたGS群9例と直視生検群27例では、両群ともに止血剤の使用割合はほぼ同等であったが、検査後の発熱や低酸素血症などの合併症の割合は11.1%、29.6%とGS群で少ない傾向にあり、また平均検査時間は43.9±15.8分、57.6±14.9分と有意にGS群で短かった(P=0.024)。結論. ガイドシースを挿入可能な直視所見を有する病変に対してEBUS-GS法は安全かつ十分な回数の生検が可能で、有用な方法であると考えられた。(著者抄録)

    DOI: 10.18907/jjsre.37.4_375

    CiNii Article

  17. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells Reviewed

    Yamashita Ryo, Sato Mitsuo, Kakumu Tomohiko, Hase Tetsunari, Yogo Naoyuki, Maruyama Eiichi, Sekido Yoshitaka, Kondo Masashi, Hasegawa Yoshinori

    CANCER MEDICINE   Vol. 4 ( 4 ) page: 551-564   2015.4

     More details

    Language:English  

    DOI: 10.1002/cam4.412

    Web of Science

  18. Immuno-wall lab-on-chip companion diagnostic devices for rapid and low-cost detection of mutant epidermal growth factor receptors (EGFR) from cytological samples in lung cancer patients

    T. Kasama, T. Hase, N. Nishiwaki, N. Yogo, M. Sato, M. Kondo, N. Kaji, M. Tokeshi, Y. Hasegawa, Y. Baba

    MicroTAS 2015 - 19th International Conference on Miniaturized Systems for Chemistry and Life Sciences     page: 925 - 927   2015

     More details

    © 15CBMS-0001. In the present study, we propose immuno-wall lab-on-a-chip companion diagnostic devices for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib. The lysates of cytological samples including pleural effusion in lung cancer patients were successfully analyzed within 20 minutes. This is the first experiment demonstrating the detection of mutated EGFRs in the pleural effusion by microdevices. Our devices have a great potential to become the next generation companion diagnostic devices which overcome the problems of currently available methods.

    Scopus

  19. マイクロRNA miR-221とmiR-222は非小細胞肺癌に二峰性に作用する

    山下 良, 佐藤 光夫, 長谷 哲成, 丸山 英一, 各務 智彦, 加藤 俊夫, 與語 直之, 近藤 征史, 長谷川 好規

    肺癌   Vol. 54 ( 5 ) page: 362 - 362   2014.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  20. 当院にて経験したEWSを用いた気管支充填術9症例の検討

    中平 健一, 今井 直幸, 松下 明弘, 大舘 満, 織田 恒幸, 加藤 俊夫, 近藤 千晶, 宮崎 晋一, 與語 直之, 渡辺 尚宏, 鈴木 嘉洋, 鈴木 妙子, 岡地 祥太郎, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 長谷川 好規

    気管支学   Vol. 36 ( Suppl. ) page: S253 - S253   2014.3

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.36.Special_S253_2

    CiNii Article

  21. 気管支閉鎖症の2例

    近藤 千晶, 渡辺 尚宏, 與語 直之, 宮崎 晋一, 加藤 俊夫, 織田 恒幸, 大舘 満, 松下 明弘, 中平 健一, 鈴木 嘉洋, 鈴木 妙子, 岡地 祥太郎, 今井 直幸, 長谷 哲成, 麻生 裕紀, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 長谷川 好規

    気管支学   Vol. 36 ( Suppl. ) page: S282 - S282   2014.3

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

  22. 当院における超音波気管支鏡ガイド下針生検(EBUS‐TBNA)施行症例の検討

    竹山佳宏, 鈴木隆二郎, 権田秀雄, 大舘満, 與語直之, 佐藤和秀, 福井保太

    気管支学   Vol. 34   page: S218   2012.5

     More details

  23. 結核性髄膜炎・脊椎カリエスを併発した若年発症の粟粒結核の1例

    大舘満, 鈴木隆二郎, 権田秀雄, 梶川茂久, 與語直之, 福井保太, 倉橋祐子

    結核   Vol. 85 ( 10 ) page: 761   2010.10

     More details

    Language:Japanese  

    J-GLOBAL

  24. 慢性咳嗽を主訴に来院したアレルギー性気管支肺真菌症の一例

    坂まりえ, 鈴木隆二郎, 権田秀雄, 伸健浩, 山下良, 與語直之, 大舘満, 福井保太, 倉橋祐子

    東三医学会誌   ( 32 ) page: 7 - 10   2010.3

     More details

    Language:Japanese  

    J-GLOBAL

  25. 治療に難渋した比較的稀な気腫性肺嚢胞合併アスペルギルス症の2例

    大原啓示, 角三和子, 中山雅人, 石川寛, 加藤毅人, 近藤弘史, 成田久仁夫, 與語直之, 近藤千紘, 鈴木隆二郎

    日本気胸・嚢胞性肺疾患学会雑誌   Vol. 9 ( 1 ) page: 102   2009.8

     More details

    Language:Japanese  

    J-GLOBAL

  26. 当科における気管支鏡検査による非結核性抗酸菌MACの検出状況

    権田秀雄, 鈴木隆二郎, 菅沼伸一, 伸健浩, 山下良, 大館満, 與語直之, 山本景三

    気管支学   Vol. 31   page: S11   2009.5

     More details

  27. 70歳代 女性 長期の経過をたどった心弁膜症

    與語直之, 木田直樹, 前多松喜

    豊橋市民病院臨床病理検討会(CPC)記録集   Vol. 3   page: 193 - 199   2009.5

     More details

    Language:Japanese  

    J-GLOBAL

  28. 70歳代 男性 動注療法を施行した急性膵炎の症例

    與語直之, 石川英樹, 前多松喜, 河崎秀陽

    豊橋市民病院臨床病理検討会(CPC)記録集   Vol. 3   page: 163 - 170   2009.5

     More details

    Language:Japanese  

    J-GLOBAL

  29. 肺大細胞癌小腸転移の1例

    大倉俊昭, 鈴木隆二郎, 菅沼伸一, 伸健浩, 山下良, 與語直之, 大舘満, 牧野壮壱, 権田秀雄, 金田成康

    東三医学会誌   ( 31 ) page: 49   2009.3

     More details

    Language:Japanese  

    J-GLOBAL

  30. 右頚部の腫瘤で発症し,剖検にてはじめて肺癌原発巣が明らかになった右肺尖部肺大細胞癌の一例

    権田秀雄, 鈴木隆二郎, 山下良, 伸健浩, 大館満, 與語直之, 福井保太, 山本景三, 近藤雅幸, 安藤豪, 松影昭一, 前多松喜

    日本気管食道科学会総会ならびに学術講演会プログラム・予稿集   Vol. 61st   page: 95   2009

     More details

    Language:Japanese  

    J-GLOBAL

▼display all

Presentations 7

  1. Immuno-wall lab-on-chip companion diagnostic devices for rapid and low-cost detection of mutant epidermal growth factor receptors (EGFR) from cytological samples in lung cancer patients

    Kasama T.

    MicroTAS 2015 - 19th International Conference on Miniaturized Systems for Chemistry and Life Sciences 

     More details

    Event date: 2015

    Language:English   Presentation type:Oral presentation (general)  

    Scopus

  2. P2-9-7 気管支閉鎖症の2例(気道狭窄,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    近藤 千晶, 鈴木 嘉洋, 鈴木 妙子, 岡地 祥太郎, 今井 直幸, 長谷 哲成, 麻生 裕紀, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 渡辺 尚宏, 長谷川 好規, 與語 直之, 宮崎 晋一, 加藤 俊夫, 織田 恒幸, 大舘 満, 松下 明弘, 中平 健一

    特定非営利活動法人 日本呼吸器内視鏡学会 

     More details

    Event date: 2014

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

    CiNii Article

  3. P1-8-1 経気管支肺生検にて確定診断がついたIntravascular large B-cell lymphomaの一例(びまん性疾患/BAL 2,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    織田 恒幸, 與語 直之, 渡辺 尚宏, 鈴木 嘉洋, 中平 健一, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 今井 直幸, 長谷川 好規, 岡地 祥太郎, 鈴木 妙子, 近藤 千晶, 松下 明弘, 大舘 満, 加藤 俊夫, 宮崎 晋一

    特定非営利活動法人 日本呼吸器内視鏡学会 

     More details

    Event date: 2014

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

    CiNii Article

  4. P1-9-6 キシロカインアレルギー症例に対してテトラカインを用いて気管支鏡を施行した2例(安全対策,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    鈴木 嘉洋, 織田 恒幸, 中平 健一, 鈴木 妙子, 岡地 祥太郎, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 今井 直幸, 長谷川 好規, 松下 明弘, 宮崎 晋一, 與語 直之, 大舘 満, 加藤 俊夫, 近藤 千晶, 渡辺 尚宏

    特定非営利活動法人 日本呼吸器内視鏡学会 

     More details

    Event date: 2014

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

    CiNii Article

  5. P1-12-2 当院にて経験したEWSを用いた気管支充填術9症例の検討(EWS 1,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    中平 健一, 渡辺 尚宏, 鈴木 嘉洋, 鈴木 妙子, 岡地 群太郎, 麻生 裕紀, 長谷 哲成, 若原 恵子, 橋本 直純, 佐藤 光夫, 近藤 征史, 今井 直幸, 長谷川 好規, 松下 明弘, 大舘 満, 織田 恒幸, 加藤 俊夫, 近藤 千晶, 宮崎 晋一, 與語 直之

    特定非営利活動法人 日本呼吸器内視鏡学会 

     More details

    Event date: 2014

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

    CiNii Article

  6. P12-3 当院における超音波気管支内視鏡ガイド下針生検(EBUS-TBNA)自験例56例の検討(EBUS3,ポスター12,第35回日本呼吸器内視鏡学会学術集会)

    佐藤 和秀, 竹山 佳宏, 梶川 茂久, 與語 直之, 大舘 満, 福井 保太, 権田 秀雄, 鈴木 隆二郎

    特定非営利活動法人 日本呼吸器内視鏡学会 

     More details

    Event date: 2012

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

    CiNii Article

  7. P12-1 当院における超音波気管支鏡ガイド下針生検(EBUS-TBNA)施行症例の検討(EBUS3,ポスター12,第35回日本呼吸器内視鏡学会学術集会)

    竹山 佳宏, 鈴木 隆二郎, 権田 秀雄, 大舘 満, 與語 直之, 佐藤 和秀, 福井 保太

    特定非営利活動法人 日本呼吸器内視鏡学会 

     More details

    Event date: 2012

    Language:Japanese   Presentation type:Poster presentation  

    Country:Japan  

    CiNii Article

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. 肺癌バイオマーカーの多項目分析のためのマイクロ免疫診断チップ開発

    Grant number:19K16796  2019.04 - Now

    平成31年度科学研究費助成事業(学術研究助成基金助成金)   若手研究

    與語 直之

      More details

    Authorship:Principal investigator 

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    一般病院において一般臨床検査として実施可能な、肺癌治療選択に直結する複数のバイオマーカーを微量検体からでも迅速・低コストに検出できるマイクロ免疫診断システムを開発する。
    そのため、肺癌細胞株由来の検体を用いて各バイオマーカーに対する市販抗体・試薬等の最適化及び検査工程の標準化をそれぞれ行った上で、既に開始している臨床研究で収集した臨床検体及び名古屋大学医学部附属病院が保有するバイオバンク検体を用いて性能評価を行う計画である。
    準備段階において、既に開発したマイクロ免疫診断チップを用いて肺癌細胞株由来検体及び既存の肺癌患者由来臨床検体における上皮成長因子受容体(EGFR)common mutation(Exon19 E746_A750del及びExon21 L858R)・野生型の検討は行っている。しかし、他にEGFR uncommon mutationとして、exon18 G719X、exon20 insertion、exon20 S768I、exon21 L861Q等があり、それぞれにおいて第一世代(ゲフィチニブ・エルロチニブ)、第二世代(アファチニブ)、第三世代(オシメルチニブ)EGFRチロシンキナーゼ阻害薬に対する奏効割合が異なるという報告がなされている。そこで、既存臨床検体におけるEGFR uncommon mutation検出に関する検討を追加し、EGFR common mutation検出に関する結果と合わせて論文投稿を行った。現在査読中である。
    また、臨床試験を継続し、引き続き順調に肺癌患者より臨床検体の収集を行っている(名古屋大学医学部生命倫理委員会承認番号:2014-0171)。
    感度向上については、Enzyme linked immuno sorbent assay(ELISA)で用いられている酵素・基質反応の応用を検討した結果、高いバックグラウンドが生じる原因として洗浄工程に問題があると考えられたため、洗浄液に用いる界面活性剤の種類・濃度を検証し最適化することで、従来の蛍光標識抗体を用いるアッセイ法の検出限界からおよそ100万倍の感度向上を達成することが可能となり、特許出願するに至った(特願2019-134763)。
    EGFR mutationについては、更に深く(uncommon mutationまで)検討することができた。
    また、性能評価で用いるべく臨床検体の収集も順調に進んでいる。
    感度向上についても、酵素・基質反応の応用によるおよそ100万倍の向上を達成することができ、より低濃度のタンパク質を標的とすることが可能となった。
    既に治療薬が臨床応用されている、EGFR以外の遺伝子(ALK・ROS1・BRAF)及びPD-L1の検出法を確立すべく、まずは各肺癌細胞株由来の検体を用いて抗体・試薬等検査工程の最適化・標準化をそれぞれ行う。
    また、感度向上については更に量子ドット等新たな検出技術の導入も検討し、最終的には血液中の超微量な標的タンパク質検出(Liquid Biopsy)を目指したい。

  2. Identification of driver genes in lung cancer through a semi-genome wide shRNA library screen based on anoikis resistance phenotype

    Grant number:26293197  2014.04 - 2017.03

    Sato Mitsuo

      More details

    Authorship:Other 

    This study was aimed to identify novel therapeutic targets for lung cancer. To this end, we employed two approached. First, we tried to identify genes that contribute to anoikis resistance by doing shRNA library screen using an immortalized normal human bronchial epithelial cell line, HBEC. Anoikis is a special type of apoptosis induced by loss of attachment to extra cellular matrix, and resistance against anoikis is one of critical malignant properties of cancer cells. We identified RNF146 as a gene whose loss could contribute to anoikis resistance in HBEC. However, this result was not reproduced in lung cancer cell lines. Second, we did an integrated analysis combining a shRNA library screen with utilization of gene expression and copy number analysis using an aggressive lung cancer cell line, H460. We identified proteasome subunit gene PSMA6 as a novel therapeutic target for lung cancer.

Industrial property rights 1

  1. 分析デバイス

     More details

    Application no:特願2019-134763  Date applied:2019.7.22